Compare Lithium Americas Corp (LAC) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lithium Americas Corp vs ResMed Inc. — how do they compare? Lithium Americas Corp trades at $2.35 (market cap $850.38M), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 37.5× Lithium Americas Corp's market cap, and ResMed Inc. pays a 1.16% dividend while Lithium Americas Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lithium Americas Corp for 27 Days and ResMed Inc. for 51 Days on average.
| LAC | RMD | |
|---|---|---|
Market Cap | $850.38M | $31.89B |
Volume | 8,804,637 | 618,314 |
Sector | Basic Materials | Health |
52-Week High | $10.05 | $275.96 |
52-Week Low | $2.35 | $182.82 |
Typical Hold Time | 27 Days | 51 Days |
Enterprise Value | $1.19B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lithium Americas (LAC) trades at $2.36, down 2.07% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -9.56% and ROA at -3.99%, while maintaining strong analyst support with 7 buy ratings and a $4.00 consensus price target. Recent financing activities and Thacker Pass project development provide growth catalysts amid challenging lithium market conditions.
LAC presents a high-risk opportunity with significant upside potential from its Thacker Pass project execution, though negative cash flow and lithium price volatility create near-term headwinds. The stock trades at a discount to analyst targets but requires successful project ramp-up to justify valuation.
ResMed (RMD) trades at $226.73, up 0.33% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming Q1 2027 earnings report and management's focus on 12%-14% EPS growth driven by demand in sleep therapy.
The outlook for RMD is positive, supported by robust fundamentals and analyst consensus, though risks include competitive pressures and ongoing legal investigations. Upside potential exists with a consensus price target of $242.70, representing a 7% increase from current levels, but investors should monitor execution against growth targets and market share dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
